A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Bacterial corneal ulcers are a leading cause of pediatric blindness in underdeveloped countries due to a lack of antibiotic availability and affordability, among other reasons. Povidone-iodine, an inexpensive and readily available broad-spectrum antimicrobial agent, may be an effective and affordable treatment for corneal ulcers, allowing preservation of sight for those afflicted with this disease.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
1 Month and older (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Clinical diagnosis of untreated bacterial corneal ulcer that began within 14 days of presentation to the study center.
Corneal ulcer size is 2 mm-8 mm. in diameter, and does not extend to the limbus.
Topical or systemic antimicrobial or immunosuppressant therapy within 14 days of presentation to the study center.
Corneal ulcer smear and culture fail to show the presence of bacteria.
Allergic history to povidone-iodine, iodine or any components of Neosporin.
Dacrocystitis, neurotropic or exposure keratitis, keratitis sicca, positive HIV status, and legal blindness in the unaffected eye.